Initializing

Gaining access to millions of annotated cells across 10+ cancer indications.

Analyzing pathology slides

Our algorithms detect and characterize tissue and cell architecture.

Calculating Features

Cell & area locations are intersected to compute over hundreds of complex feature values.

Predicting Response

Deep-learning models combining spatial features and clinical data drive the discovery of pathology based spatial biomarkers.

Initializing

Gaining access to millions of annotated cells across 10+ cancer indications.

Analyzing pathology slides

Our algorithms detect and characterize tissue and cell architecture.

Calculating Features

Cell & area locations are intersected to compute over hundreds of complex feature values.

Predicting Response

Deep-learning models combining spatial features and clinical data drive the discovery of pathology based spatial biomarkers.

PRODUCTS

Our Offering

ABOUT US

We are transforming precision medicine with AI-powered pathology

Our team’s work is a unique collaboration of experienced AI technologists, physicians and exceptional healthcare research professionals.

Exploratory Research Platform

Our Platform empowers researchers to discover novel, human interpretable pathology-based biomarkers that predict response to therapy, identify genomic markers or explain complex biological phenomena at scale.

AI-Powered Clinical Trial Assays

Qualified biomarkers are incorporated into prospective clinical trials via Nucleai’s AI-powered digital assays. In partnership with CROs and central laboratories, we support a compliant (FDA, CLIA, GxP) and scalable patient selection process.

Companion Diagnostics Development

In partnership with biopharma, diagnostics and clinical laboratories, we develop and deploy Nucleai’s digital assays as companion diagnostics across the world, providing physicians with the best diagnostic tools to improve patient lives.

Our Platform

Nucleai’s platform unlocks spatial insights. In Nucleai Atom, your pathology slides are transformed into raw data of cell and area locations. The raw data is fed into the Nucleai engine, computing hundreds of spatial features intersected with outcome to predict drug response.

DATA & INSTITUTIONAL PARTNERS

INVESTORS

SCIENTIFIC PUBLICATIONS

LEADERSHIP

CAREERS

Join Us in Biomarker Discovery

At Nucleai, we bring physicians and researchers cutting edge AI-based technology that identifies pathology-based biomarkers that can predict response to therapy and significantly improve patient outcomes. Come join our team of experienced AI engineers, world renowned clinicians, and others, to revolutionize precision medicine and make a major impact.
Head of Research

Head of Research

Tel Aviv

Medical Data Specialist Full Time

Medical Data Specialist Full Time

Tel Aviv

Medical Data Specialist Part Time

Medical Data Specialist Part Time

Tel Aviv

Scientific Program manager

Scientific Program manager

United States

Senior Full-stack Software Engineer

Senior Full-stack Software Engineer

Tel Aviv

Senior Researcher

Senior Researcher

Tel Aviv

NEWS & UPDATES

Nucleai, Propath Partnership Paves Way for Spatial Oncology Biomarkers

Spatial biology specialists Nucleai and Propath UK have announced a partnership to develop and validate an immunofluorescence assay focused on 30 immuno-oncology protein targets that could inform the development of novel oncology biomarkers and companion diagnostics. Dr Ken Bloom, head of Pathology at Nucleai, explained that spatial biology—the study of tissues within their multidimensional context—“is considered a new frontier and […]

Read More

Nucleai and Propath UK announce partnership for end-to-end AI-powered spatial analysis of a 30-plex immunofluorescence immuno-oncology panel

Propath UK, Europe’s leading CRO for spatial biology, and Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking spatial biology insights from pathology data, announce their collaboration to develop and validate a 30-plex immunofluorescence (IF) panel focused on protein targets relevant to immuno-oncology. For our pharmaceutical and biotechnology partners, this groundbreaking panel, in […]

Read More

Lunaphore and Nucleai announce a partnership to provide AI-powered spatial biology analysis to accelerate drug development

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data, today announced a collaboration to accelerate the discovery of novel biomarkers and drug targets using the latest spatial imaging and machine learning technologies. […]

Read More

Nucleai Announces New Data Showing Better Prediction of Response to Immune Checkpoint Inhibitors for NSCLC Patients

Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data, today announced new data showing that the deep learning capabilities of the Nucleai platform accurately analyzed and classified the spatial arrangement of immune cells in the tumor microenvironment (TME) to identify metastatic non-small cell lung cancer (mNSCLC) patients […]

Read More

Nucleai Appoints New Head of Pathology to Support Expansion in Biopharmaceutical and Clinical Markets

Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data, today announced the appointment of Kenneth J. Bloom, MD, FCAP as the company’s new head of pathology. Dr. Bloom brings more than 35 years of clinical experience in pathology, oncology, telemedicine and bioinformatics to this critical role at […]

Read More

Nucleai Announces a Partnership with Sirona Dx for AI-Driven Discovery of Novel Spatial Biomarkers in Solid Tumors

Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data, and Sirona Dx, a leading provider of multiomic single-cell analytical services, today announced a collaboration to advance the discovery of novel spatial biomarkers in solid tumors. The partnership combines Nucleai’s powerful AI spatial analytics platform with Sirona Dx’s […]

Read More

Add Your Heading Text Here